Monitor for patient enrollment updates and interim data readouts from the Phase IIb trial. The stock is highly speculative given the $2M market cap and pre-revenue status; any safety or efficacy signals could drive outsized moves.
Price Chart
Executive Summary
SciSparc's subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, a cannabinoid-based treatment for Tourette Syndrome. The trial builds on Phase IIa data showing a 21% average tic reduction. This is a clinical milestone for a pre-revenue micro-cap with a $2M market cap, but no financial data or near-term revenue catalyst is provided.
Key Facts
- Phase IIb trial site initiated at Hannover Medical School for SCI-110 in Tourette Syndrome
- Phase IIa showed 21% average tic reduction across participants
- Trial is randomized, double-blind, placebo-controlled, cross-over design
- Additional sites: Yale Child Study Center and Tel Aviv Sourasky Medical Center
- Primary endpoint: change in tic severity at weeks 12 and 26 vs baseline
- Market cap is approximately $2M; company is pre-revenue with no financial data in this filing
Financial Impact
No financial data provided in the filing; pre-revenue clinical-stage company
Risk Factors
- Clinical trial failure or negative efficacy/safety data
- Dilution risk from future capital raises given pre-revenue status and $2M market cap
- Regulatory and enrollment delays across multiple international sites
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-078316 |
| Document: ea029809502ex99-1.htm | 0001213900-26-078316 |
| Document: 0001213900-26-078316-index-headers.html | 0001213900-26-078316 |
| Document: 0001213900-26-078316-index.html | 0001213900-26-078316 |
| Document: 0001213900-26-078316.txt | 0001213900-26-078316 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.09 (+15.47%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.09 (+0.00%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.09 (−9.17%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.09 (+45.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.09 (−45.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.09 (−45.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.09 (−76.51%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.09 (+76.04%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.09 (−79.78%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.09 (−78.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers